Observational studyClinical interventions in aging2026
Serum Peroxiredoxin 6 Levels and Clinical Outcomes After Acute Intracerebral Hemorrhage in Elderly Patients: A Multicenter Observational Analytical Study.
Observational study in Clinical interventions in aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intracerebral hemorrhage (ICH) is commonly encountered in elderly patients. Peroxiredoxin 6 (Prx6) is involved in oxidative stress and inflammatory responses. Here, serum Prx6 levels were measured to explore their prognostic value in ICH. Methods: In this multicenter observational analytical study of 306 elderly patients with ICH and 100 elderly controls, serum Prx6 levels were quantified at admission of all patients, at serial time points of 103 patients and at study entry of controls. Outcome variables included early neurological deterioration (END) and poor neurological status mirrored by six-month modified Rankin Scale (mRS). Results: Serum Prx6 levels were significantly elevated upon admission of patients, gradually increased on day 1, peaked on day 3, decreased from day 5 until day 14 after ICH, and were markedly higher during 14 days than those of controls. Serum Prx6 levels, in independent correlation with National Institutes of Health Stroke Scale scores, hematoma sizes and mRS scores, were linearly related to risks of END and poor prognosis, and independently predicted their occurrences. The independent associations were robust in sensitivity analysis. The association between serum Prx6 levels and poor prognosis was partially mediated by END. Serum Prx6 levels showed an effective predictive ability for poor prognosis and END. Other parameters, such as age, gender, and hypertension, negligibly affected the relevance of Prx6 levels in poor prognosis and END. The combined models encompassing independent predictors were visualized via the nomograms and had acceptable goodness of fit and clinical benefit via various statistical tools. Conclusion: Elevated serum Prx6 levels post-ICH in the elderly are intimately related to bleeding severity and clinical outcomes; and END partially interprets the association of serum Prx6 with poor prognosis, therefore suggesting that serum Prx6 may be a prognostic biomarker of ICH in the elderly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.